Nitrates supplemented with L-arginine for the reversal and treatment of nitrate tolerance: Two case reports

Applied Cardiopulmonary Pathophysiology

Volumn 6, Issue 4, 1996, Pages 255-262

  Kaesemeyer, W H ^a,b,c   Abou Mohamed, G ^a,b   Crute, T D ^a,b   Caldwell, R W ^a,b  

^a Augusta Hypertension PC   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c AUGUSTA STATE UNIVERSITY   (United States)

Author keywords

L arginine; Myocardial infarction; Nitrate tolerance; Nitric oxide; Organic nitrates; Unstable angina

Indexed keywords

ARGININE; NITRATE; NITRIC OXIDE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CASE REPORT; DRUG TOLERANCE; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; UNSTABLE ANGINA PECTORIS; VASCULAR SMOOTH MUSCLE;

EID: 0030422724     PISSN: 09205268     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Stcwart DD. Remarkable tolerance to nitroglycerin. Philadelphia Polyclinic 18««; 172-5.
2. Laursen JB, Boesgaard S. Poulson HE, Aldcrshvile J. Nitrate tolerance: impaired vascular effects of stimulation and inhibition of nitric oxide release in vivo [abstract]. J Am Coll Cardiol 1995; 115A.
3. Gruetter CA. Lemke SM. Dissociation of cysteine in glutathione levels from nitroglycerin induced relaxation. Eur J Pharmacol 1985: 111:85-95.
4. Parker JO, Parker JD. Neurohormonal activation during nitrate therapy: a possible mechanism for tolerance. (A symposium: Third North American Conference on Nitroglycerin Therapy.) Am J Cardiol 1992; 70: 93B-97B.
5. Gold ME, Bush PA, Ignarro LJ. Depletion of arterial L-arginine causes reversible tolerance to endothelium-dependent relaxation. Biuchem Biophys Res Comm 1989: 164: 714-21.
6. Sehröder H. Barann M. Bennet BM, Lcitman DC. Crosstolerance to L-arginine-dependent guanylate cyclase activators in nitrate tolerant LLC-PK1 kidney epithelial cells. Pol J Pharmacol Pharm 1990; 42: 259-63.
7. Flaherty JT. Comparison of intravenous nitroglycerin and sodium nitroprusside in acute myocardial infarction. Am J Med 1983:53-60.
8. Ahou-Mohamed G, Kacsemeyer WH. Papapetropoulos A, Catravas JD, Caldwell RW. Nitroglycerin (NTG) but not sodi-um nitroprusside (SNP), increases aortic ring cGMP levels via an L-arginine dependent and L-NAME sensitive pathway [abstract]. FASEB J 1993; 9: A327.
9. Abou-Mohamed G, Suarez A, Kaesemeyer WH, Papapelropoulos A, Catravas JD, Caldwell RW. L-arginine in the development and reversal of tolerance nitroglycerin [abstract]. FASEB J 1996: 10:3, A569.
10. Bibber RV. Traub O, Kroll K, Fcigl ED. EDRF and norepinephrine-induccd vasodilation in the canine coronary circulation. Am J Physiol 1995; 268: H1973-H1981.
11. Xabregas D. Stokes J. Nitric oxide. L-arginine, hypertension and cardiopulmonary bypass: Three case reports. Appl Cardiopulmon Pathophysiol 1995: 5: 231-6.
12. Malta E. Biphasic relaxant curves to glycerol trinitrate in rat aortic rings. Evidence for two mechanisms of action. Arch Pharmacol 1989; 339: 230-43.
13. Malta E. Studies on the hiphasic relaxant curve of glycerol trinitrate in rat aorta: role of GTN metabolites. Clin Exp Pharmacol Physiol 1989; 16: II. «29-35.
14. Moncada S. Palmer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharm Rev 1991; 43: 11)9-42.
15. Culcasi M. Lafon-Cazal M, Pietri S, Bockaert J. Glutamate receptors induce a hurst of Superoxide via activation of nitric oxide syntheses in arginine-deplcted neurons. J Biol Cheni 1994:269:12589-93.
16. Mayer B, Mathias J, Hcinzel B. Werner ER. Wächter H, Schullz G, Böhmer E. Brain nitric oxide syntheses is a bioptcrin- and Ravin-containing multifunctional oxido-reductase. FEBS Lett 1991; 288: 187-91.
17. Pou S. Pou WS. Bredt DS, Snyder SH. Rosen GM. Generation of Superoxide by purified brain nitric oxide synthase. J Biol Chcm 1992; 267: 24173-6.
18. Griffith OW, Stueler DJ. Nitric oxide synthesis: properties and catalytic mechanism. Ann Rev Physiol 1995: 57: 707-36.
19. Miinzel T, Saycgh H. Freeman BA, Tarpcy MM, Harrison DG. Evidence for enhanced vascular Superoxide anion production in nitrate tolerance. A novel vascular Superoxide anion production in nitrate tolerance. A novel mechanism underlying nitrate tolerance and cross tolerance. J Clin Invest 1995: 95: 187-94.
20. Stamler JS. Singel DJ. Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992; 258: 1898-1902.
21. SneddonJM, BearparkTM, Galton SA, Vane JR. Transport and metabolism of L-argininc by bovine aortic endothelial cells. In: S. Moncada, E.A. Higgs (eds) Nitric oxide from L-arginine: a hioregulatory system. Elsevier Science Publishers. 1990: 457-61.
22. ISIS-4 Collaborative Group. A randomized factorial trial assessing early oral captopril. oral mononitrate, and intravenous magnesium substrate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85.
23. Yao S, Ober J. Krishnaswami A. Fcrguson J, Andcrson HV, Golini P, Buju LM. Willcrson JT. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations instenosedandcndothelium-injured arteries. Circulation 1992; 86: 1302-9.
24. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein llb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
25. Nakaki T. Hishikawa K. Suzuki H, Saruta T, Kalo R. L-arginine induced hypotension [Letter]. Lancet 1990; 336: 696.
26. Oalver A. Collier J, Vallence P. Dilator actions of L-arginine in human peripheral vasculature. din Sei I99I: 81: 695-700.
27. Rhodes P, Barr C, Struthers AD. Is L-arginine induced vasodilation really due to providing slereospecific substrate for NO synthase? [abstract] Br Heart J 1995; 73 Suppl. 3: 12.
28. Calver A, Macallister R, Edwards M, Herreous B, Nussey S, Collier J, Vallence P. Vascular and hormonal effects of L-arginine in health and hypertension: Provision of substrate for nitric oxide (NO) or non-specific effects? [abstract] Br Heart J 1995; 73 Suppl. 3: 12.
29. Kaesemeyer WH, inventor and assignee. Method and formulation of stimulating nitric oxide synthesis. US patent 5,543,430. 19% August 6.
30. Address for correspondence: W.H. Kaesemeyer, Augusta Hypertension, PC, Suite 2 Bio Tech Park, 1021 15th Street, Augusta, Georgia, 30901, USA, E-mail: HTN007@juno.com